By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alethia BioTherapeutics, Inc. 

141, Président-Kennedy ave.
Suite SB-5100
Montreal  Quebec  H2X 1Y4  Canada
Phone: 514-858-7666 Fax: 514-858-5333




Company News
Goodwin Biotechnology, Inc. Announces a Collaboration With Alethia BioTherapeutics, Inc. 6/2/2011 10:06:13 AM
Alethia BioTherapeutics, Inc. Secures C$9.6 Million in Series A Financing to Fund Its Therapeutic Monoclonal Antibody Product Pipeline 9/7/2010 6:29:42 AM
Alethia BioTherapeutics, Inc. Strengthens its Board of Directors 12/15/2009 10:09:03 AM
Alethia BioTherapeutics, Inc. Announces in-Licensing of a Peptide for Imaging of Solid Tumors in vivo and Positive Pre-Clinical Results of AB-16B5 in Prostate and Breast Cancer 12/7/2009 10:52:33 AM
Alethia BioTherapeutics, Inc. Exercises its Option to License Clusterin-Specific Antibodies for Cancer Therapeutics and Diagnostics 5/6/2009 7:20:03 AM
Alethia BioTherapeutics, Inc. Closes $2.2 M Financing - Proceeds to Advance Pre-Clinical Development of Lead Drug Candidates 4/23/2009 11:57:03 AM
BDC Venture Capital and GO Capital Invest in Alethia BioTherapeutics, Inc., a Montreal Biotechnology Firm 4/3/2008 9:51:23 AM
Alethia BioTherapeutics, Inc. Announces in-Licensing of Family of Monoclonal Antibodies to Treat Metastatic Cancer 10/3/2007 8:32:15 AM
Alethia BioTherapeutics, Inc. and Emerillon Therapeutics Inc. Announce Collaborative Agreement for Target Discovery in Bone-Related Diseases 5/1/2007 11:01:55 AM
Alethia BioTherapeutics, Inc. Announces Collaborative Agreement With Biosite Incorporated (BSTE) for Antibody Development in Ovarian Cancer 3/12/2007 10:19:02 AM